ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $21,568.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $53.92, for a total transaction of $21,568.00. Following the sale, the vice president now directly owns 55,588 shares in the company, valued at $2,997,304.96. This trade represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

ANI Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ:ANIP traded down $1.11 during mid-day trading on Monday, reaching $53.93. The stock had a trading volume of 478,176 shares, compared to its average volume of 201,225. The firm has a 50 day simple moving average of $56.58 and a two-hundred day simple moving average of $59.03. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81. The firm has a market cap of $1.13 billion, a PE ratio of -98.05 and a beta of 0.73. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same period last year, the firm posted $1.05 earnings per share. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. State Street Corp raised its position in shares of ANI Pharmaceuticals by 9.1% during the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after purchasing an additional 58,698 shares during the period. Dimensional Fund Advisors LP raised its holdings in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock worth $40,132,000 after buying an additional 21,053 shares during the period. Pacer Advisors Inc. lifted its stake in ANI Pharmaceuticals by 23,259.8% in the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after buying an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after buying an additional 340,854 shares during the period. Finally, Global Alpha Capital Management Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after buying an additional 9,500 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Leerink Partners initiated coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Truist Financial lifted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.